NGM BIOPHARMACEUTICALS INC
Reported by THE BANK OF NEW YORK MELLON CORPORATION
Reported 0 shares, down 133,225 (100.0%) from the prior quarter.
Reported value -100.0%; share count -100.0% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2021-09-30 | 2465000 |
| 2021-12-31 | 2278000 |
| 2022-03-31 | 2021000 |
| 2022-06-30 | 1677000 |
| 2022-09-30 | 1970000 |
| 2022-12-31 | 669743 |
| 2023-03-31 | 541391 |
| 2023-06-30 | 361398 |
| 2023-09-30 | 148886 |
| 2023-12-31 | 119478 |
| 2024-03-31 | 211827 |
| 2024-06-30 | 0 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q2 2024 | Reduced | 0 | -133,225 (-100.0%) | 0 | $0 | 2024-07-25 | |
| Q1 2024 | Reduced | 133,225 | -5,865 (-4.2%) | < 0.01% | $211,827 | 2024-04-25 | |
| Q4 2023 | Reduced | 139,090 | -55 (0.0%) | < 0.01% | $119,478 | 2024-01-29 | |
| Q3 2023 | Reduced | 139,145 | -391 (-0.3%) | < 0.01% | $148,886 | 2023-10-24 | |
| Q2 2023 | Added | 139,536 | +6,842 (5.2%) | < 0.01% | $361,398 | 2023-08-03 | |
| Q1 2023 | Reduced | 132,694 | -721 (-0.5%) | < 0.01% | $541,391 | 2023-05-09 | |
| Q4 2022 | Reduced | 133,415 | -17,214 (-11.4%) | < 0.01% | $669,743 | 2023-02-14 | |
| Q3 2022 | Added | 150,629 | +19,840 (15.2%) | < 0.01% | $1,970,000 | 2022-11-14 | |
| Q2 2022 | Reduced | 130,789 | -1,725 (-1.3%) | < 0.01% | $1,677,000 | 2022-08-15 | |
| Q1 2022 | Added | 132,514 | +3,893 (3.0%) | < 0.01% | $2,021,000 | 2022-05-11 | |
| Q4 2021 | Added | 128,621 | +11,387 (9.7%) | < 0.01% | $2,278,000 | 2022-02-11 | |
| Q3 2021 | Added | 117,234 | +15,843 (15.6%) | < 0.01% | $2,465,000 | 2021-11-12 | |
|
Five years are shown. A free account unlocks the complete reported history.
Unlock full history
|
|||||||
Who else reported the position
74 managers reported NGM BIOPHARMACEUTICALS INC for Q2 2024.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| BlackRock Inc | Reduced | 0 | -3,004,210 | 0 | $0 | 21 qtrs |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | Reduced | 0 | -4,381 | 0 | $0 | 21 qtrs |
| EXCHANGE TRADED CONCEPTS LLC | Reduced | 0 | -186,232 | 0 | $0 | 5 qtrs |
| GSA CAPITAL PARTNERS LLP | Reduced | 0 | -33,529 | 0 | $0 | 8 qtrs |
| NEW YORK STATE COMMON RETIREMENT FUND | Reduced | 0 | -10,252 | 0 | $0 | 21 qtrs |
| Engineers Gate Manager LP | Reduced | 0 | -22,269 | 0 | $0 | 4 qtrs |
| NISA INVESTMENT ADVISORS LLC | Reduced | 0 | -75 | 0 | $0 | 20 qtrs |
| NATIXIS | Reduced | 0 | -181,366 | 0 | $0 | 2 qtrs |
| STATE STREET CORPORATION | Reduced | 0 | -823,111 | 0 | $0 | 21 qtrs |
| GEODE CAPITAL MANAGEMENT LLC | Reduced | 0 | -983,836 | 0 | $0 | 21 qtrs |
Filing details and methodology As reported
- Report period
- June 30, 2024
- Filed
- July 25, 2024
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.